Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of secukinumab in polymyalgia rheumatica (PMR) relapsing after core study
jRCT2031240079Recruiting
- Sponsor
- Novartis
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Open-label, single-arm trial of secukinumab in polymyalgia rheumatica (PMR), sponsored by Novartis. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence of serious adverse events. Started Jun 2024; status: recruiting.
02
Drugs
secukinumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on jRCT2031240079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240079.